Comparative analysis of glycemic outcomes following implementation of a pharmacist-led insulin management service in postoperative cardiothoracic surgery patients

IF 1.5 Q4 PHARMACOLOGY & PHARMACY Journal of the American College of Clinical Pharmacy : JACCP Pub Date : 2025-02-05 DOI:10.1002/jac5.2079
Sydney Kermeen Pharm.D., Brittany White Pharm.D., Alicia Stowe M.S., Christopher Wilson Pharm.D.
{"title":"Comparative analysis of glycemic outcomes following implementation of a pharmacist-led insulin management service in postoperative cardiothoracic surgery patients","authors":"Sydney Kermeen Pharm.D.,&nbsp;Brittany White Pharm.D.,&nbsp;Alicia Stowe M.S.,&nbsp;Christopher Wilson Pharm.D.","doi":"10.1002/jac5.2079","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Perioperative hyperglycemia is a predictor of mortality in cardiothoracic surgery (CTS) patients. Cardiothoracic surgery patients with diabetes have improved clinical outcomes with maintained glycemic management, including improved hospital length of stay (LOS), surgical site infection risk, and rates of morbidity and mortality. A pharmacist-led insulin management service was implemented, granting pharmacists autonomy to adjust basal, bolus, and infusion insulin regimens to optimize glycemic management following CTS. Literature evaluating the impact on glycemic management in CTS patients following a pharmacist-led insulin management service is limited.</p>\n </section>\n \n <section>\n \n <h3> Objective</h3>\n \n <p>The study objective was to compare postoperative glycemic management in CTS patients before and after implementation of a pharmacist-led insulin management service.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This retrospective study included adult CTS patients with diabetes with a hemoglobin A1c (HbA1c) of 6.5% or greater who received at least 2 basal insulin doses following postoperative intravenous (IV) insulin infusion. The primary outcome was the percentage of blood glucose concentrations within the target range (70–180 mg/dL) until postoperative Day 7 or discharge, if sooner. Secondary outcomes were average daily blood glucose, time to discontinuation of postoperative IV insulin infusion, incidence of hypoglycemia and hyperglycemia requiring re-initiation of an insulin infusion, hospital LOS, and postoperative surgical site infections within 3 months.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 200 patients were included, 100 in each group. Mean percent of glucose checks within target range was higher in the post-implementation group compared with the pre-implementation group (60.8 vs. 48.9, <i>p</i> = 0.0004). The post-implementation group achieved a lower mean daily blood glucose (170 vs. 191, <i>p</i> &lt; 0.0001) and spent fewer days on postoperative insulin infusion (1.24 vs. 1.85, <i>p</i> &lt; 0.0001). There were no differences in the incidence of hypoglycemia, re-initiation of insulin infusion, LOS, or surgical site infections.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Implementation of a pharmacist-led insulin management service was a safe and effective strategy to improve glycemic management in postoperative CTS patients.</p>\n </section>\n </div>","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"8 2","pages":"116-122"},"PeriodicalIF":1.5000,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the American College of Clinical Pharmacy : JACCP","FirstCategoryId":"1085","ListUrlMain":"https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/jac5.2079","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

Perioperative hyperglycemia is a predictor of mortality in cardiothoracic surgery (CTS) patients. Cardiothoracic surgery patients with diabetes have improved clinical outcomes with maintained glycemic management, including improved hospital length of stay (LOS), surgical site infection risk, and rates of morbidity and mortality. A pharmacist-led insulin management service was implemented, granting pharmacists autonomy to adjust basal, bolus, and infusion insulin regimens to optimize glycemic management following CTS. Literature evaluating the impact on glycemic management in CTS patients following a pharmacist-led insulin management service is limited.

Objective

The study objective was to compare postoperative glycemic management in CTS patients before and after implementation of a pharmacist-led insulin management service.

Methods

This retrospective study included adult CTS patients with diabetes with a hemoglobin A1c (HbA1c) of 6.5% or greater who received at least 2 basal insulin doses following postoperative intravenous (IV) insulin infusion. The primary outcome was the percentage of blood glucose concentrations within the target range (70–180 mg/dL) until postoperative Day 7 or discharge, if sooner. Secondary outcomes were average daily blood glucose, time to discontinuation of postoperative IV insulin infusion, incidence of hypoglycemia and hyperglycemia requiring re-initiation of an insulin infusion, hospital LOS, and postoperative surgical site infections within 3 months.

Results

A total of 200 patients were included, 100 in each group. Mean percent of glucose checks within target range was higher in the post-implementation group compared with the pre-implementation group (60.8 vs. 48.9, p = 0.0004). The post-implementation group achieved a lower mean daily blood glucose (170 vs. 191, p < 0.0001) and spent fewer days on postoperative insulin infusion (1.24 vs. 1.85, p < 0.0001). There were no differences in the incidence of hypoglycemia, re-initiation of insulin infusion, LOS, or surgical site infections.

Conclusion

Implementation of a pharmacist-led insulin management service was a safe and effective strategy to improve glycemic management in postoperative CTS patients.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
心胸外科术后患者实施药师主导胰岛素管理服务后血糖结局的比较分析
围手术期高血糖是心胸外科(CTS)患者死亡率的预测因子。通过维持血糖管理,心胸手术合并糖尿病患者的临床结果得到改善,包括住院时间(LOS)、手术部位感染风险、发病率和死亡率的改善。实施了药剂师主导的胰岛素管理服务,赋予药剂师自主调整基础、大剂量和输注胰岛素方案,以优化CTS后的血糖管理。评估CTS患者接受药剂师主导的胰岛素管理服务对血糖管理影响的文献有限。目的比较药师主导胰岛素管理服务实施前后CTS患者的术后血糖管理情况。方法本回顾性研究纳入了糖化血红蛋白(HbA1c)为6.5%或更高的成人CTS糖尿病患者,这些患者术后静脉注射胰岛素后接受了至少2次基础胰岛素剂量。主要终点是术后第7天或出院前血糖浓度在目标范围(70-180 mg/dL)内的百分比。次要结局是平均每日血糖、术后静脉胰岛素输注停止时间、低血糖和高血糖需要重新开始胰岛素输注的发生率、医院LOS和术后3个月内手术部位感染。结果共纳入200例患者,每组100例。与实施前组相比,实施后组血糖检查在目标范围内的平均百分比更高(60.8比48.9,p = 0.0004)。实施后组的日均血糖较低(170比191,p < 0.0001),术后胰岛素输注天数较少(1.24比1.85,p < 0.0001)。在低血糖、重新开始胰岛素输注、LOS或手术部位感染的发生率方面没有差异。结论实施药师主导的胰岛素管理服务是改善CTS术后患者血糖管理的一种安全有效的策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
2.70
自引率
0.00%
发文量
0
期刊最新文献
Impact of an In-House Resident Clinical Pharmacist On-Call Program on Resident Physician Training: A Cross-Sectional Survey The Current Landscape of Anticoagulation Stewardship Implementation in the United States and Around the World: An International Survey Impact of Pharmacist-Led Antimicrobial Stewardship on Antibiotic Use in Intensive Care: A Prospective Audit and Feedback Approach Clinical Pharmacists and Industry: Guidelines for Professional Interactions Optimizing Antimicrobial Stewardship in Hospital-at-Home Programs: On Behalf of the Society of Infectious Diseases Pharmacists
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1